vs
Side-by-side financial comparison of FVCBankcorp, Inc. (FVCB) and ROCKWELL MEDICAL, INC. (RMTI). Click either name above to swap in a different company.
ROCKWELL MEDICAL, INC. is the larger business by last-quarter revenue ($18.3M vs $16.9M, roughly 1.1× FVCBankcorp, Inc.). On growth, FVCBankcorp, Inc. posted the faster year-over-year revenue change (4377.5% vs -25.6%). FVCBankcorp, Inc. produced more free cash flow last quarter ($23.8M vs $2.2M). Over the past eight quarters, FVCBankcorp, Inc.'s revenue compounded faster (586.6% CAGR vs -10.1%).
FVCBankcorp, Inc. is a Virginia-based U.S. bank holding company operating FVCbank, a community-focused financial institution. It provides a full range of personal and commercial banking products including deposit accounts, business and personal loans, mortgage services, and wealth management solutions, serving SMEs, professionals and individual consumers across the Mid-Atlantic region.
Rockwell Medical Inc. is a publicly traded pharmaceutical company based in Wixom, Michigan and founded in 1996 that focuses on development and commercialization of treatments against diseases such as end-stage renal disease (ESRD) and chronic kidney disease (CKD).
FVCB vs RMTI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.9M | $18.3M |
| Net Profit | — | $-554.0K |
| Gross Margin | — | 21.1% |
| Operating Margin | 43.7% | -2.2% |
| Net Margin | — | -3.0% |
| Revenue YoY | 4377.5% | -25.6% |
| Net Profit YoY | — | 26.7% |
| EPS (diluted) | $0.31 | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.9M | $18.3M | ||
| Q3 25 | $416.0K | $15.9M | ||
| Q2 25 | $15.8M | $16.1M | ||
| Q1 25 | $382.0K | $18.9M | ||
| Q4 24 | $378.0K | $24.7M | ||
| Q3 24 | $412.0K | $28.3M | ||
| Q2 24 | $415.0K | $25.8M | ||
| Q1 24 | $359.0K | $22.7M |
| Q4 25 | — | $-554.0K | ||
| Q3 25 | $5.6M | $-1.8M | ||
| Q2 25 | $5.7M | $-1.5M | ||
| Q1 25 | $5.2M | $-1.5M | ||
| Q4 24 | — | $-756.0K | ||
| Q3 24 | $4.7M | $1.7M | ||
| Q2 24 | $4.2M | $343.0K | ||
| Q1 24 | $1.3M | $-1.7M |
| Q4 25 | — | 21.1% | ||
| Q3 25 | — | 14.3% | ||
| Q2 25 | — | 15.6% | ||
| Q1 25 | — | 16.1% | ||
| Q4 24 | — | 14.7% | ||
| Q3 24 | — | 22.0% | ||
| Q2 24 | — | 17.6% | ||
| Q1 24 | — | 13.5% |
| Q4 25 | 43.7% | -2.2% | ||
| Q3 25 | — | -9.9% | ||
| Q2 25 | 45.9% | -8.4% | ||
| Q1 25 | — | -7.2% | ||
| Q4 24 | — | -2.1% | ||
| Q3 24 | — | 6.8% | ||
| Q2 24 | — | 2.0% | ||
| Q1 24 | — | -5.8% |
| Q4 25 | — | -3.0% | ||
| Q3 25 | 1341.1% | -11.0% | ||
| Q2 25 | 36.0% | -9.3% | ||
| Q1 25 | 1352.1% | -8.0% | ||
| Q4 24 | — | -3.1% | ||
| Q3 24 | 1133.3% | 5.9% | ||
| Q2 24 | 1001.2% | 1.3% | ||
| Q1 24 | 373.3% | -7.6% |
| Q4 25 | $0.31 | $-0.01 | ||
| Q3 25 | $0.31 | $-0.05 | ||
| Q2 25 | $0.31 | $-0.05 | ||
| Q1 25 | $0.28 | $-0.04 | ||
| Q4 24 | $0.27 | $-0.02 | ||
| Q3 24 | $0.25 | $0.04 | ||
| Q2 24 | $0.23 | $0.01 | ||
| Q1 24 | $0.07 | $-0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $10.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $253.6M | $37.0M |
| Total Assets | $2.3B | $57.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $10.7M | ||
| Q3 25 | — | $13.6M | ||
| Q2 25 | — | $12.5M | ||
| Q1 25 | — | $11.4M | ||
| Q4 24 | — | $15.7M | ||
| Q3 24 | — | $12.3M | ||
| Q2 24 | — | $11.9M | ||
| Q1 24 | — | $6.6M |
| Q4 25 | $253.6M | $37.0M | ||
| Q3 25 | $249.8M | $37.0M | ||
| Q2 25 | $243.2M | $30.4M | ||
| Q1 25 | $242.3M | $31.5M | ||
| Q4 24 | $235.4M | $32.6M | ||
| Q3 24 | $230.8M | $29.1M | ||
| Q2 24 | $226.5M | $23.5M | ||
| Q1 24 | $220.7M | $20.6M |
| Q4 25 | $2.3B | $57.1M | ||
| Q3 25 | $2.3B | $57.5M | ||
| Q2 25 | $2.2B | $52.6M | ||
| Q1 25 | $2.2B | $54.0M | ||
| Q4 24 | $2.2B | $59.2M | ||
| Q3 24 | $2.3B | $57.1M | ||
| Q2 24 | $2.3B | $53.0M | ||
| Q1 24 | $2.2B | $50.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $23.9M | $2.3M |
| Free Cash FlowOCF − Capex | $23.8M | $2.2M |
| FCF MarginFCF / Revenue | 140.7% | 12.0% |
| Capex IntensityCapex / Revenue | 0.3% | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $40.0M | $-1.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $23.9M | $2.3M | ||
| Q3 25 | $7.6M | $-1.3M | ||
| Q2 25 | $3.3M | $1.8M | ||
| Q1 25 | $5.4M | $-3.5M | ||
| Q4 24 | $18.2M | $865.0K | ||
| Q3 24 | $4.7M | $4.3M | ||
| Q2 24 | $1.6M | $1.4M | ||
| Q1 24 | $7.2M | $-2.4M |
| Q4 25 | $23.8M | $2.2M | ||
| Q3 25 | $7.6M | $-1.5M | ||
| Q2 25 | $3.3M | $1.7M | ||
| Q1 25 | $5.4M | $-3.5M | ||
| Q4 24 | $18.1M | $470.0K | ||
| Q3 24 | $4.6M | $4.1M | ||
| Q2 24 | $1.5M | $1.2M | ||
| Q1 24 | $7.1M | $-2.5M |
| Q4 25 | 140.7% | 12.0% | ||
| Q3 25 | 1818.0% | -9.6% | ||
| Q2 25 | 20.8% | 10.5% | ||
| Q1 25 | 1413.6% | -18.8% | ||
| Q4 24 | 4786.0% | 1.9% | ||
| Q3 24 | 1121.8% | 14.4% | ||
| Q2 24 | 361.2% | 4.5% | ||
| Q1 24 | 1988.3% | -11.1% |
| Q4 25 | 0.3% | 0.5% | ||
| Q3 25 | 0.2% | 1.4% | ||
| Q2 25 | 0.1% | 1.0% | ||
| Q1 25 | 4.2% | 0.3% | ||
| Q4 24 | 37.3% | 1.6% | ||
| Q3 24 | 14.1% | 0.7% | ||
| Q2 24 | 12.8% | 1.1% | ||
| Q1 24 | 3.9% | 0.6% |
| Q4 25 | — | — | ||
| Q3 25 | 1.36× | — | ||
| Q2 25 | 0.58× | — | ||
| Q1 25 | 1.05× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.00× | 2.57× | ||
| Q2 24 | 0.37× | 4.20× | ||
| Q1 24 | 5.34× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FVCB
Segment breakdown not available.
RMTI
| US | $15.9M | 87% |
| Non Us | $2.4M | 13% |
